
|Articles|December 4, 2007
Open letter from Genentech
Click here to read Genentech's open letter to ophthalmologists, outlining its reason for imposing restrictions on the use of Avastin.
Advertisement
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
How Digital Workflow Boosted my Confidence and Elevated Premium Patient Rates in Cataract Surgery
2
From skepticism to clarity and focus: A family’s PRESBYOND experience
3
Evolving Practice In Retinal Care A Question Of Control
4
Real-World Burden of Demodex Blepharitis in the UK
5















































